185 related articles for article (PubMed ID: 27330056)
1. Immunotherapy of Cancer Visualized by Live Microscopy: Seeing Is Believing.
Teijeira A; Etxeberria I; Ponz-Sarvise M; Melero I
Clin Cancer Res; 2016 Sep; 22(17):4277-9. PubMed ID: 27330056
[TBL] [Abstract][Full Text] [Related]
2. In Vivo Fluorescence Imaging of the Activity of CEA TCB, a Novel T-Cell Bispecific Antibody, Reveals Highly Specific Tumor Targeting and Fast Induction of T-Cell-Mediated Tumor Killing.
Lehmann S; Perera R; Grimm HP; Sam J; Colombetti S; Fauti T; Fahrni L; Schaller T; Freimoser-Grundschober A; Zielonka J; Stoma S; Rudin M; Klein C; Umana P; Gerdes C; Bacac M
Clin Cancer Res; 2016 Sep; 22(17):4417-27. PubMed ID: 27117182
[TBL] [Abstract][Full Text] [Related]
3. Neoantigens in the immuno-oncology space.
Arlen PM
Future Oncol; 2017 Oct; 13(25):2209-2211. PubMed ID: 28976211
[No Abstract] [Full Text] [Related]
4. Cancer Immunotherapy: The Dawn of Antibody Cocktails.
Marrocco I; Romaniello D; Yarden Y
Methods Mol Biol; 2019; 1904():11-51. PubMed ID: 30539465
[TBL] [Abstract][Full Text] [Related]
5. Bispecific antibodies for cancer therapy.
Hollander N
Immunotherapy; 2009 Mar; 1(2):211-22. PubMed ID: 20635943
[TBL] [Abstract][Full Text] [Related]
6. Current perspectives of bispecific antibody-based immunotherapy.
Talac R; Nelson H
J Biol Regul Homeost Agents; 2000; 14(3):175-81. PubMed ID: 11037049
[TBL] [Abstract][Full Text] [Related]
7. Harnessing T cells to fight cancer with BiTE® antibody constructs--past developments and future directions.
Klinger M; Benjamin J; Kischel R; Stienen S; Zugmaier G
Immunol Rev; 2016 Mar; 270(1):193-208. PubMed ID: 26864113
[TBL] [Abstract][Full Text] [Related]
8. Bispecific Antibodies in the Treatment of Hematologic Malignancies.
Duell J; Lammers PE; Djuretic I; Chunyk AG; Alekar S; Jacobs I; Gill S
Clin Pharmacol Ther; 2019 Oct; 106(4):781-791. PubMed ID: 30770546
[TBL] [Abstract][Full Text] [Related]
9. Alternative molecular formats and therapeutic applications for bispecific antibodies.
Spiess C; Zhai Q; Carter PJ
Mol Immunol; 2015 Oct; 67(2 Pt A):95-106. PubMed ID: 25637431
[TBL] [Abstract][Full Text] [Related]
10. Inhibiting complement regulators in cancer immunotherapy with bispecific mAbs.
Gelderman KA; Lam S; Gorter A
Expert Opin Biol Ther; 2005 Dec; 5(12):1593-601. PubMed ID: 16318423
[TBL] [Abstract][Full Text] [Related]
11. PLAC1: biology and potential application in cancer immunotherapy.
Mahmoudian J; Ghods R; Nazari M; Jeddi-Tehrani M; Ghahremani MH; Ghaffari-Tabrizi-Wizsy N; Ostad SN; Zarnani AH
Cancer Immunol Immunother; 2019 Jul; 68(7):1039-1058. PubMed ID: 31165204
[TBL] [Abstract][Full Text] [Related]
12. Genetically Engineered Multivalent Proteins for Targeted Immunotherapy.
Talmadge JE
Clin Cancer Res; 2016 Jul; 22(14):3419-21. PubMed ID: 27009744
[TBL] [Abstract][Full Text] [Related]
13. Recombinant bispecific antibodies for cellular cancer immunotherapy.
Müller D; Kontermann RE
Curr Opin Mol Ther; 2007 Aug; 9(4):319-26. PubMed ID: 17694444
[TBL] [Abstract][Full Text] [Related]
14. Predictive Biomarkers for PD-1 Axis Therapies: The Hidden Treasure or a Call for Research.
Schalper KA; Kaftan E; Herbst RS
Clin Cancer Res; 2016 May; 22(9):2102-4. PubMed ID: 26957559
[TBL] [Abstract][Full Text] [Related]
15. Human cancer detection and immunotherapy with conjugated and non-conjugated monoclonal antibodies.
Bodey B; Siegel SE; Kaiser HE
Anticancer Res; 1996; 16(2):661-74. PubMed ID: 8687112
[TBL] [Abstract][Full Text] [Related]
16. Chimeric antigen receptors and bispecific antibodies to retarget T cells in pediatric oncology.
Suzuki M; Curran KJ; Cheung NK
Pediatr Blood Cancer; 2015 Aug; 62(8):1326-36. PubMed ID: 25832831
[TBL] [Abstract][Full Text] [Related]
17. Bispecific antibodies and diabodies for cancer immunotherapy.
Elsässer-Beile U; Bühler P
Immunotherapy; 2012 May; 4(5):459-60. PubMed ID: 22642325
[No Abstract] [Full Text] [Related]
18. Antibodies for neoplastic disease solid tumors.
Matthews IT
Mol Biotechnol; 2002 May; 21(1):91-7. PubMed ID: 11989663
[No Abstract] [Full Text] [Related]
19. Bispecific antibodies engage T cells for antitumor immunotherapy.
Choi BD; Cai M; Bigner DD; Mehta AI; Kuan CT; Sampson JH
Expert Opin Biol Ther; 2011 Jul; 11(7):843-53. PubMed ID: 21449821
[TBL] [Abstract][Full Text] [Related]
20. The "Achilles' Heel" of Cancer and Its Implications for the Development of Novel Immunotherapeutic Strategies.
Joshi K; Chain BM; Peggs KS; Quezada SA
Cold Spring Harb Perspect Med; 2018 Jan; 8(1):. PubMed ID: 28630228
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
